小细胞肺癌伴1-10个脑转移患者立体定向放射外科治疗:多机构II期前瞻性临床试验
该单臂多中心II期试验纳入100例小细胞肺癌伴1-10个脑转移患者,评估立体定向放疗后神经性死亡率为11.0%(95%CI 5.8-18.1),低于WBRT历史对照的17.5%,仅22%需挽救性WBRT,支持立体定向方法在该人群的应用。
要点
- 小细胞肺癌伴1-10个脑转移患者接受SRS/SRT后1年神经性死亡率为11.0%(95%CI 5.8-18.1)。
- WBRT历史对照的神经性死亡率为17.5%。
- 仅22%患者需挽救性WBRT,中位总生存期为10.2个月。
核心结论
- 前瞻性多机构研究显示,小细胞肺癌伴1-10个脑转移患者接受SRS/SRT而非WBRT并密切监测后神经性死亡率低,支持立体定向方法在该人群的应用。
研究设计与样本
- 单臂、多中心、II期临床试验(ClinicalTrials.gov标识符:NCT03391362)。
- 2018年2月至2023年4月共纳入100例小细胞肺癌或胸外小细胞原发伴1-10个脑转移的患者。
- 不允许既往脑部放疗包括预防性颅脑照射。
- 神经性死亡定义为明显的、进行性影像学脑进展伴相应神经症状,无全身性疾病进展或危及生命的全身症状。
- SRS/SRT后采用密切的脑部影像学监测。
主要发现
- 脑转移中位数为2个(IQR 1-4;范围1-10)。
- 中位总生存期为10.2个月;仅22%患者需要挽救性WBRT。
- 共观察到20例神经性死亡,相对64例非神经性死亡。
- 1年神经性死亡率为11.0%(95%CI 5.8-18.1);WBRT管理患者的历史率为17.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362). METHODS: Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used. RESULTS: Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%. CONCLUSION: Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.
引用
- Aizer AA, Tanguturi SK, Shi DD, et al. Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial. J Clin Oncol. 2025. PMID: 40644657. doi:10.1200/JCO-25-00056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。